Abstract:The endocannabinoid signaling system is a ubiquitous means of (sub) cellular information transduction. Investigation of the system’s molecular components and the biochemical processes they participate in was stimulated some 25 years ago by seminal evidence that Δ9-tetrahydrocannabinol (Δ9-THC), the principal psychoactive component of Cannabis sp., exerts its psychotropic effects mainly through engaging and activating a class-A (rhodopsin-like) G protein-coupled receptor (GPCR), cannabinoid receptor 1 (CB1R), in the central nervous system. Subsequent investigations have explored the mechanisms of action of other phytocannabinoids (e.g., cannabidiol) and the principal endogenous cannabinoid lipid transmitters in humans and other mammals [the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG)], leading to the identification of an additional cannabinoid receptor [cannabinoid receptor 2 (CB2R)] and insight into the key physiological roles of the enzymes monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH) in terminating, respectively, 2-AG and AEA signaling functions. The importance of the endocannabinoid system in regulating many biological processes has stimulated the design and synthesis of structurally diverse small molecules as candidate therapeutics targeted to CB1R, CB2R, MGL, or FAAH. Given the increasing prevalence of legalized social and medicinal cannabis use and the emergence of ultra-potent, synthetic cannabinoids as illicit “street drugs,” current medicinal chemistry efforts aim to address the public health problems presented by cannabis use disorders (CUDs), both acute (e.g., cannabis overdose) and chronic (i.e., addiction). Within this context, this review discusses various therapeutic modalities targeted to CB1R, CB2R, MGL, and FAAH and highlights their potential to yield CUD therapies. Intrinsic pharmacological properties of CB1R neutral antagonists and MGL and FAAH inhibitors are regarded as key to potentially safe and efficacious medications for treating acute cannabis toxicity and/or CUDs.

Structural Basis for Molecular Recognition of Cannabinoids by Inhibitory Cys-Loop Channels

Modulation of the Cys-loop Ligand-Gated Ion Channels by Fatty Acid and Cannabinoids.

Bioinformatic Analysis of CBDA1 Gene in Cannabis sativa

The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders

Structural Basis of Signaling of Cannabinoids Receptors: Paving a Way for Rational Drug Design in Controling Mutiple Neurological and Immune Diseases

Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures

Crystal Structure of the Human Cannabinoid Receptor CB2

Structural and Functional Insights into Cannabinoid Receptors

Effects of cannabinoids on ligand-gated ion channels

Crystal Structure of the Human Cannabinoid Receptor CB1

Molecular biology of cannabinoid receptors

A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.

Cannabinoids and Cannabinoid Receptors: The Story so Far

New Insights in Cannabinoid Receptor Structure and Signaling

Predicting the molecular interactions of CRIP1a-cannabinoid 1 receptor with integrated molecular modeling approaches.

Actomyosin-mediated nanostructural remodeling of the presynaptic vesicle pool by cannabinoids induces long-term depression

Molecular characterization of a peripheral receptor for cannabinoids

Exploring the evolutionary trajectory and functional landscape of cannabinoid receptors: A comprehensive bioinformatic analysis

Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development

Cannabinoid inhibition of mechanosensitive K+ channels

Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products